Disclosure Of Entity's Operating Segments [Text Block]

Xspray Pharma - Filing #679275

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Disclosure of entity's operating segments [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of operating segments [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue	—	—	– SEK	—	—	—	—	—	—	– SEK	—	—	—
Tax expense (income)	—	—	17,000 SEK	—	—	—	—	—	—	– SEK	—	—	—
Profit (loss) before tax	—	—	179 684 SEK	—	—	—	—	—	—	131 670 SEK	—	—	—
Profit (loss)	- SEK	- SEK	179 667 SEK	—	179 667 SEK	- SEK	—	– SEK	– SEK	131 670 SEK	131 670 SEK	- SEK	– SEK
Assets	—	—	—	765 263 SEK	—	—	585 430 SEK	—	—	—	—	—	—
Cash flows from (used in) operating activities	—	—	203 275 SEK	—	—	—	—	—	—	110 179 SEK	—	—	—
Cash flows from (used in) investing activities	—	—	65 876 SEK	—	—	—	—	—	—	135 345 SEK	—	—	—
Cash flows from (used in) financing activities	—	—	315 594 SEK	—	—	—	—	—	—	93 809 SEK	—	—	—
Disclosure of products and services [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of major customers [abstract]
Disclosure of major customers [line items]